AVITA Medical Appoints Cary Vance as Permanent CEO, Jan Stern Reed as Board Chair; Discloses Substantial Equity Compensation Plan

summarizeSummary

AVITA Medical has appointed Cary Vance as its permanent President and CEO, solidifying leadership after an interim period, and also named Jan Stern Reed as Board Chair. The new CEO's compensation package includes substantial equity grants subject to future shareholder approval.

check_boxKey Events

• Permanent CEO Appointment

  Cary Vance, previously Interim CEO and Executive Chairman since October 2025, has been appointed President and Chief Executive Officer, effective April 30, 2026, following a thorough search process.

• Board Leadership Change

  Jan Stern Reed, who served as Lead Independent Director since October 2025, has been appointed Chair of the Board of Directors, effective immediately. Her previous role as Lead Independent Director has been terminated.

• CEO Compensation Package Detailed

  Mr. Vance's new employment agreement includes an annual base salary of $702,000, an 80% target annual bonus opportunity, and planned equity grants totaling $3,354,000 (comprising 50% restricted stock units and 50% stock options for an initial grant of $2,529,000, plus an additional RSU grant of $825,000 for interim service). These equity awards are subject to shareholder approval at the 2027 Annual Meeting of Stockholders.

auto_awesomeAnalysis

This 8-K filing signals a critical step in stabilizing AVITA Medical's leadership, particularly important given the company's recent 'going concern' warning. The permanent appointment of Cary Vance, who has served as Interim CEO, provides continuity and a clear strategic direction. The substantial planned equity compensation package for Mr. Vance, while subject to future shareholder approval, reflects the company's commitment to attracting and retaining executive talent. The appointment of Jan Stern Reed as Board Chair further strengthens corporate governance. Investors will likely view these leadership confirmations as a positive development for the company's long-term stability and ability to navigate its financial challenges.